A fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers superior to Pfizer's revised $8.1 billion bid. Legal challenges have emerged as both companies vie for control of the lucrative obesity drug market. Metsera's shares have seen significant gains amidst this intense competition.